3,5-Dimethyl-isoxazol-4-acetamid | 893641-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3,5-Dimethyl-isoxazol-4-acetamid
• 英文别名: 2-(3,5-dimethyl-isoxazol-4-yl)-acetamide；2-(3,5-Dimethylisoxazol-4-yl)acetamide；2-(3,5-dimethyl-1,2-oxazol-4-yl)acetamide
• CAS: 893641-80-0
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD08701377
• 分子量: 154.169
• InChiKey: GNKYGZKKLUVDPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-Dimethyl-isoxazol-4-acetamid 在 三氯氧磷 作用下， 反应 1.25h， 生成 2-(3,5-dimethylisoxazol-4-yl)acetonitrile
  参考文献：
  名称：

  蝶啶。8.一些2,4,7-三氨基-6-杂芳基蝶啶。

  摘要：

  DOI：

  10.1021/jm00309a032
• 作为产物：
  描述：

  ethyl 2-(3,5-dimethylisoxazol-4-yl)acetate 在 氨 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 3,5-Dimethyl-isoxazol-4-acetamid
  参考文献：
  名称：

  蝶啶。8.一些2,4,7-三氨基-6-杂芳基蝶啶。

  摘要：

  DOI：

  10.1021/jm00309a032

文献信息

• SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：CZECHTIZKY Werngard

  公开号：US20130065859A1

  公开（公告）日：2013-03-14

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色甘醇-6-氧基)-噻唑衍生物，其中Ar、R2、R3和R4如权利要求中所定义。式I的化合物是钠-钙交换蛋白（NCX）的抑制剂，特别是亚型1的钠-钙交换蛋白（NCX1），适用于处理细胞内钙离子稳态受扰的各种疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140243292A1

  公开（公告）日：2014-08-28

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色烯-6-氧基)-噻唑，其中Ar，R2，R3和R4如权利要求所定义。公式I化合物是钠钙交换器（NCX）的抑制剂，特别是钠钙交换器亚型1（NCX1）的抑制剂，并适用于治疗细胞内钙离子稳态受到干扰的多种疾病，如心律失常，心力衰竭和中风。本发明还涉及制备公式I化合物的方法，它们作为药物的用途，以及包含它们的制药组合物。
• PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS
  申请人：RAQUALIA PHARMA INC.

  公开号：US20150291582A1

  公开（公告）日：2015-10-15

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑吡啶衍生物，其具有钠离子电压门控通道的阻滞活性，包括TTX-S通道，并且可用于治疗或预防涉及钠离子电压门控通道的疾病和疾病。本发明还涉及包括这些化合物的制药组合物以及在预防或治疗涉及钠离子电压门控通道的疾病中使用这些化合物和组合物的用途。
• Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
  申请人：SANOFI

  公开号：EP2567958B1

  公开（公告）日：2014-10-29
• QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS
  申请人：ConverGene LLC

  公开号：EP2968360B1

  公开（公告）日：2021-01-20